SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 3,317 Shares of Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 3,317 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $16.77, for a total transaction of $55,626.09. Following the completion of the sale, the chief financial officer owned 256,560 shares in the company, valued at $4,302,511.20. This represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Price Performance

SIBN stock opened at $17.79 on Tuesday. The company has a market capitalization of $788.99 million, a P/E ratio of -45.47 and a beta of 0.67. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.99. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89. The business has a 50-day simple moving average of $14.79 and a two-hundred day simple moving average of $15.49.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The firm had revenue of $52.59 million during the quarter, compared to the consensus estimate of $51.16 million. Research analysts expect that SiBone will post -0.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SIBN. TD Cowen cut their price objective on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Truist Financial reissued a “buy” rating and set a $18.00 price target (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of SiBone in a research note on Thursday. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, SiBone currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone during the 4th quarter worth $29,000. Versant Capital Management Inc grew its position in SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after buying an additional 887 shares during the period. Royal Bank of Canada increased its holdings in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in SiBone by 64,700.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after acquiring an additional 1,941 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new stake in SiBone in the fourth quarter worth about $53,000. Institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.